Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Licenses RNA, DNA Standards Technology to BD for MDx Development

NEW YORK (GenomeWeb News) – Asuragen today announced it has granted Becton Dickinson the rights to incorporate its Armored RNA technology into BD's in vitro molecular diagnostic products.

Asuragen will develop and supply reagents for BD Diagnostics in Asuragen's cGMP manufacturing facility under the terms of the deal. Other details of the non-exclusive worldwide agreement were not disclosed.

Armored RNA was jointly invented and developed by Asuragen and Cenetron Diagnostics to create RNA and DNA standards for molecular diagnostic assays. The technology has been incorporated into most HIV and HCV commercially available diagnostic assays that measure viral load, Austin, Texas-based Asuragen said.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.